| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
20,430,000 |
| Market
Cap: |
1.37(B) |
| Last
Volume: |
2,387,520 |
Avg
Vol: |
2,380,888 |
| 52
Week Range: |
$38.04 - $69.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ANI Pharmaceuticals is a bio-pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include: Candesartan Hydrochlorothiazide, Fenofibrate, Fluvoxamine, Hydrocortisone Enema, Lithium Carbonate ER, Mesalamine, Propranolol ER, Terbutaline, and Vancomycin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
254,921 |
421,551 |
1,262,027 |
1,480,093 |
| Total Sell Value |
$16,747,919 |
$26,516,522 |
$74,515,877 |
$82,888,946 |
| Total People Sold |
8 |
9 |
12 |
12 |
| Total Sell Transactions |
23 |
40 |
87 |
90 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Raynor Daniel |
Director |
– • – |
2013-07-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,345,849 |
|
- |
|
| Arnold Charlotte C. |
Chief Financial Officer |
• – – |
2013-06-19 |
4/A |
A |
$0.00 |
$0 |
I/I |
0 |
0 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2013-06-19 |
4/A |
A |
$0.00 |
$0 |
I/I |
0 |
0 |
|
- |
|
| Meridian Venture Partners Ii, Co. |
10% Owner |
– – • |
2013-06-19 |
4 |
A |
$0.00 |
$0 |
I/I |
16,918,469 |
16,918,469 |
|
- |
|
| Jamnick Robert J. |
VP, Quality & Product Develop. |
• – – |
2013-06-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(138,254) |
273,710 |
|
- |
|
| Jamnick Robert J. |
VP, Quality & Product Develop. |
• – – |
2013-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
411,964 |
411,964 |
|
- |
|
| Przybyl Arthur |
President and CEO |
• • – |
2013-06-19 |
4 |
A |
$0.00 |
$0 |
I/I |
1,966,489 |
1,966,489 |
|
- |
|
| Arnold Charlotte C. |
VP & Chief Financial Officer |
• – – |
2013-06-19 |
4 |
A |
$0.00 |
$0 |
I/I |
595,246 |
595,246 |
|
- |
|
| Marken James G. |
Vice President, Operations |
• – – |
2013-06-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(145,629) |
289,612 |
|
- |
|
| Marken James G. |
Vice President, Operations |
• – – |
2013-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
435,241 |
435,241 |
|
- |
|
| Penn Thomas A. |
Director |
– • • |
2013-06-19 |
4 |
A |
$0.00 |
$0 |
I/I |
16,918,469 |
16,918,469 |
|
- |
|
| Marshbanks Tracy |
Director |
– • – |
2013-06-19 |
4 |
A |
$0.00 |
$0 |
I/I |
4,850,645 |
51,778 |
|
- |
|
| Rosenow Edward C III |
Director |
– • – |
2011-11-14 |
4 |
B |
$2.37 |
$7,110 |
D/D |
3,000 |
20,540 |
2.39 |
- |
|
| Sullivan Louis |
Director |
– • – |
2011-08-15 |
4 |
B |
$2.67 |
$26,700 |
D/D |
10,000 |
47,898 |
2.39 |
- |
|
| Mangano Ross J |
Director |
– • – |
2011-08-12 |
4 |
B |
$2.40 |
$60,000 |
I/I |
25,000 |
73,333 |
2.1 |
- |
|
| Donenberg Philip B |
Sr. VP of Finance, CFO & Secy |
• – – |
2011-08-08 |
4 |
B |
$2.23 |
$2,230 |
D/D |
1,000 |
44,322 |
2.66 |
- |
|
| Donenberg Philip B |
Sr. VP of Finance, CFO & Secy |
• – – |
2011-08-05 |
4 |
B |
$2.19 |
$2,190 |
D/D |
1,000 |
43,322 |
2.66 |
- |
|
| Mangano Ross J |
Director |
– • – |
2011-08-05 |
4 |
B |
$2.21 |
$176,800 |
D/D |
80,000 |
165,756 |
2.39 |
- |
|
| Donenberg Philip B |
Sr. VP of Finance, CFO & Secy |
• – – |
2011-01-21 |
4 |
B |
$1.88 |
$1,880 |
D/D |
1,000 |
42,322 |
2.66 |
- |
|
| Donenberg Philip B |
Sr. VP of Finance, CFO & Secy |
• – – |
2011-01-19 |
4 |
B |
$1.88 |
$1,880 |
D/D |
1,000 |
41,322 |
2.66 |
- |
|
| Simes Stephen M |
Vice Chairman, President & CEO |
• • – |
2011-01-18 |
4 |
B |
$1.77 |
$8,849 |
I/I |
5,000 |
202,167 |
2.58 |
- |
|
| Sullivan Louis |
Director |
– • – |
2011-01-13 |
4 |
B |
$1.72 |
$17,200 |
D/D |
10,000 |
37,898 |
2.39 |
- |
|
| Mangano Ross J |
Director |
– • – |
2010-12-07 |
4 |
B |
$1.47 |
$29,400 |
I/I |
20,000 |
1,929,661 |
2.1 |
- |
|
| Sherwin Stephen A |
Director |
– • – |
2009-10-14 |
4 |
A |
$0.00 |
$0 |
D/D |
86,760 |
86,760 |
|
- |
|
| Potts John T Jr |
Director |
– • – |
2009-10-14 |
4 |
A |
$0.00 |
$0 |
D/D |
5,581 |
5,581 |
|
- |
|
722 Records found
|
|
Page 23 of 29 |
|
|
0.14 (0.21%) 
